A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
- 1 January 2011
- journal article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 1 (-1), 1-8
- https://doi.org/10.3816/cbc.2011.n.011
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2010
- Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparisonBMC Cancer, 2010
- Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Annals of Oncology, 2009
- Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnti-Cancer Drugs, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerThe New England Journal of Medicine, 2008
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Pharmacological Effects of Formulation VehiclesClinical Pharmacokinetics, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958